Shares of Portage Biotech Inc. surged more than 150% on Tuesday morning, reaching levels last seen in late September. The ...

After spending most of the year hunting for options to stay afloat, cash-strapped Portage Biotech appears to have found ...

Portage Biotech stock is trading higher after the company announced it signed a letter of intent with Immunova for the ...

Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to ...

Portage Biotech, a clinical-stage immuno-oncology company, focuses on the development of innovative therapies that aim to transform the immune system’s ability to fight cancer. Their pipeline is ...

Shares of Portage Biotech Inc (PRTG) are up nearly 200% at $9.14 in premarket trading, following the announcement of a Letter of ...

Shares of Portage Biotech more than doubled after the company said it has entered into a letter of intent to sell one of its subsidiaries to Immunova. The stock was changing hands at $7.33 in early ...

US equity futures were down ahead of Tuesday's opening bell as the Federal Reserve kicks off its policy-setting meeting. Dow Jones Industrial Average futures were down 0.5%, S&P 500 futures slipped 0.

Portage Biotech (PRTG) has entered into a Letter of Intent with Immunova, a private Connecticut-based biotechnology company. Under the terms of ...

Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted ...